Asia-Pacific Intravenous Immunoglobulin Market Forecast to 2028

Report Code : BMIRE00027576 | Region : Asia Pacific | Industry : Pharmaceuticals | Published Date : 05/Dec/2022
Asia-Pacific Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)

The APAC intravenous immunoglobulin market is expected to grow from US$ 2,609.61 million in 2022 to US$ 4,156.85 million by 2028. It is estimated to grow at a CAGR of 8.1% from 2022 to 2028.

Strong Pipeline Candidates for IVIG

Leading players in the intravenous immunoglobulin market have multiple projects, and many biological products in pipelines are based on proprietary technology. For instance, Evolve Biologics aims to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. The company is developing a portfolio of product candidates, IVIG, which completed its Phase III clinical trial in February 2021. Similarly, Biotest is a global company that offers plasma protein products and biotherapeutic drugs. The company is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases. In September 2020, the company completed its phase III trial investigating IgG Next Generation for patients with primary immunodeficiency disease (PID). Thus, strong pipeline candidates for IVIG are expected to become a trend in the intravenous immunoglobulin market.

Market Overview

Asia Pacific (APAC) is the fastest-growing regional market for intravenous immunoglobulin. China, India, Japan, South Korea, Australia, and the Rest of APAC are the major contributors to the market in this region. Asia Pacific is likely to account for over 21.68% market share of the global intravenous immunoglobulin market in 2022 due to the increasing geriatric population, the rising prevalence of immune deficiency disorders, and the increasing adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Therefore, the region holds huge potential for the intravenous immunoglobulin market players to grow during the forecast period. China is a developing country in Asia Pacific with a well-established healthcare system and a fast-growing pharmaceutical industry. China is home to various medical, pharmaceutical, and biotechnology product manufacturing companies operating in the global market. China also has over 300 medical contract research organizations, along with prominent biopharmaceutical product manufacturers—including China Biologic Products Holdings, Inc. and Shanghai RAAS. These pharmaceutical companies are prone to global market competition, which encourages them to introduce innovative products, thereby boosting the growth of the intravenous immunoglobulin market.

APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

APAC Intravenous Immunoglobulin Market Segmentation

The APAC intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

Based on application, the APAC intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022. Based on distribution channel, the APAC intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022. Based on end user, the APAC intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022. Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China dominated the market in 2022. ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.

● ADMA Biologics, Inc.

● Bio Products Laboratory Ltd.

● CSL Behring (CSL Limited)

● Grifols, S.A.

● Kedrion S.p.A

● Octapharma AG

● Pfizer Inc.

● Prothya Biosolutions B.V.

● Shanghai RAAS

● Takeda Pharmaceutical Company Limited

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 APAC Intravenous Immunoglobulin Market – By Type

1.3.2 APAC Intravenous Immunoglobulin Market – By Application

1.3.3 APAC Intravenous Immunoglobulin Market – By Distribution Channel

1.3.4 APAC Intravenous Immunoglobulin Market – By End User

1.3.5 APAC Intravenous Immunoglobulin Market – By Country

2. APAC Intravenous Immunoglobulin Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. APAC Intravenous Immunoglobulin Market – Market Landscape

4.1 Overview

4.2 APAC PEST Analysis

4.3 Expert Opinion

5. APAC Intravenous Immunoglobulin Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Immunodeficiency Diseases

5.1.2 Increasing Geriatric Population

5.2 Market Restraints

5.2.1 Adverse Effects of Immunoglobulin Therapy

5.3 Market Opportunities

5.3.1 Growing Pharmaceutical Industry

5.4 Future Trends

5.4.1 Strong Pipeline Candidates for IVIG

5.5 Impact Analysis

6. Intravenous Immunoglobulin Market– APAC Analysis

6.1 APAC Intravenous Immunoglobulin Market Revenue Forecast and Analysis

7. APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type

7.1 Overview

7.2 APAC Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)

7.3 IgG

7.3.1 Overview

7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)

7.4 IgM

7.4.1 Overview

7.4.2 IgM - Revenue and Forecast to 2028 (US$ Million)

7.5 IgA

7.5.1 Overview

7.5.2 IgA - Revenue and Forecast to 2028 (US$ Million)

7.6 IgE

7.6.1 Overview

7.6.2 IgE - Revenue and Forecast to 2028 (US$ Million)

7.7 IgD

7.7.1 Overview

7.7.2 IgD - Revenue and Forecast to 2028 (US$ Million)

8. APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application

8.1 Overview

8.2 APAC Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)

8.3 Hypogammaglobulinemia

8.3.1 Overview

8.3.2 Hypogammaglobulinemia - Market Revenue and Forecast to 2028 (US$ Million)

8.4 Chronic Inflammatory Demyelinating Polyneuropathy

8.4.1 Overview

8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecast to 2028 (US$ Million)

8.5 Immunodeficiency Diseases

8.5.1 Overview

8.5.2 Immunodeficiency Diseases - Market Revenue and Forecast to 2028 (US$ Million)

8.6 Myasthenia Gravis

8.6.1 Overview

8.6.2 Myasthenia Gravis - Market Revenue and Forecast to 2028 (US$ Million)

8.7 Multifocal Motor Neuropathy

8.7.1 Overview

8.7.2 Multifocal Motor Neuropathy - Market Revenue and Forecast to 2028 (US$ Million)

8.8 Idiopathic Thrombocytopenic Purpura

8.8.1 Overview

8.8.2 Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecast to 2028 (US$ Million)

8.9 Inflammatory Myopathies

8.9.1 Overview

8.9.2 Inflammatory Myopathies - Market Revenue and Forecast to 2028 (US$ Million)

8.10 Specific Antibody Deficiency

8.10.1 Overview

8.10.2 Specific Antibody Deficiency - Market Revenue and Forecast to 2028 (US$ Million)

8.11 Guillain-Barre Syndrome

8.11.1 Overview

8.11.2 Guillain-Barre Syndrome - Market Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

9. APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel

9.1 Overview

9.2 APAC Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

10. APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User

10.1 Overview

10.2 APAC Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)

10.4 Specialty Clinics

10.4.1 Overview

10.4.2 Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)

10.5 Others

10.5.1 Overview

10.5.2 Others - Market Revenue And Forecasts To 2028 (US$ Million)

11. APAC Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Overview

11.1.1 Asia Pacific: Intravenous Immunoglobulin Market, by Country, 2022 & 2028 (%)

11.1.1.1 China: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 China: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.1.3 China: Intravenous Immunoglobulin Market, By Type – 2019–2028 (US$ Million)

11.1.1.1.4 China: Intravenous Immunoglobulin Market, by Application – 2019–2028 (US$ Million)

11.1.1.1.5 China: Intravenous Immunoglobulin Market, By Distribution Channel – 2019–2028 (US$ Million)

11.1.1.1.6 China: Intravenous Immunoglobulin Market, by End User – 2019–2028 (US$ Million)

11.1.1.2 Japan: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Japan: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.2.3 Japan: Intravenous Immunoglobulin Market, By Type – 2019–2028 (US$ Million)

11.1.1.2.4 Japan: Intravenous Immunoglobulin Market, by Application – 2019–2028 (US$ Million)

11.1.1.2.5 Japan: Intravenous Immunoglobulin Market, By Distribution Channel – 2019–2028 (US$ Million)

11.1.1.2.6 Japan: Intravenous Immunoglobulin Market, by End User – 2019–2028 (US$ Million)

11.1.1.3 India Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 India: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.3.3 India: Intravenous Immunoglobulin Market, By Type – 2019–2028 (US$ Million)

11.1.1.3.4 India: Intravenous Immunoglobulin Market, by Application – 2019–2028 (US$ Million)

11.1.1.3.5 India: Intravenous Immunoglobulin Market, By Distribution Channel – 2019–2028 (US$ Million)

11.1.1.3.6 India: Intravenous Immunoglobulin Market, by End User – 2019–2028 (US$ Million)

11.1.1.4 Australia: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.4.1 Overview

11.1.1.4.2 Australia: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.4.3 Australia: Intravenous Immunoglobulin Market, By Type – 2019–2028 (US$ Million)

11.1.1.4.4 Australia: Intravenous Immunoglobulin Market, by Application – 2019–2028 (US$ Million)

11.1.1.4.5 Australia: Intravenous Immunoglobulin Market, By Distribution Channel – 2019–2028 (US$ Million)

11.1.1.4.6 Australia: Intravenous Immunoglobulin Market, by End User – 2019–2028 (US$ Million)

11.1.1.5 South Korea: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.5.1 Overview

11.1.1.5.2 South Korea: Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.5.3 South Korea: Intravenous Immunoglobulin Market, By Type – 2019–2028 (US$ Million)

11.1.1.5.4 South Korea: Intravenous Immunoglobulin Market, by Application – 2019–2028 (US$ Million)

11.1.1.5.5 South Korea: Intravenous Immunoglobulin Market, By Distribution Channel – 2019–2028 (US$ Million)

11.1.1.5.6 South Korea: Intravenous Immunoglobulin Market, by End User – 2019–2028 (US$ Million)

11.1.1.6 Rest of Asia Pacific: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.1 Overview

11.1.1.6.2 Rest of Asia Pacific: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.3 Rest of Asia Pacific: Intravenous Immunoglobulin Market, By Type – 2019–2028 (US$ Million)

11.1.1.6.4 Rest of Asia Pacific: Intravenous Immunoglobulin Market, by Application – 2019–2028 (US$ Million)

11.1.1.6.5 Rest of Asia Pacific: Intravenous Immunoglobulin Market, By Distribution Channel – 2019–2028 (US$ Million)

11.1.1.6.6 Rest of Asia Pacific: Intravenous Immunoglobulin Market, by End User – 2019–2028 (US$ Million)

12. APAC Intravenous Immunoglobulin Market–Industry Landscape

12.1 Overview

12.2 Inorganic Growth Strategies

12.2.1 Overview

12.3 Organic Growth Strategies

12.3.1 Overview

13. Company Profiles

13.1 Takeda Pharmaceutical Company Limited

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Grifols, S.A.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Pfizer Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 ADMA Biologics, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Bio Products Laboratory Ltd.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Shanghai RAAS

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Octapharma AG

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Kedrion S.p.A

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 CSL Behring (CSL Limited)

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Prothya Biosolutions B.V.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Intravenous Immunoglobulin Market

Table 1.             APAC Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

Table 2.             China: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million).

Table 3.             China: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 4.             China: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 5.             China: Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Japan: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million).

Table 7.             Japan: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Japan: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Japan: Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 10.          India: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million).

Table 11.          India: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 12.          India: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028  (US$ Million)

Table 13.          India: Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Australia: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million).

Table 15.          Australia: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Australia: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Australia: Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 18.          South Korea: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million).

Table 19.          South Korea: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 20.          South Korea: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 21.          South Korea: Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Rest of Asia Pacific: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million).

Table 23.          Rest of Asia Pacific: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 24.          Rest of Asia Pacific: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 25.          Rest of Asia Pacific: Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 26.          Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market

Table 27.          Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market

Table 28.          Glossary of Terms in Intravenous Immunoglobulin Market

● ADMA Biologics, Inc.

● Bio Products Laboratory Ltd.

● CSL Behring (CSL Limited)

● Grifols, S.A.

● Kedrion S.p.A

● Octapharma AG

● Pfizer Inc.

● Prothya Biosolutions B.V.

● Shanghai RAAS

● Takeda Pharmaceutical Company Limited

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC intravenous immunoglobulin market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the APAC intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the intravenous immunoglobulin market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Asia-Pacific Intravenous Immunoglobulin Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry